Challenges and opportunities for cancer stem cell‐targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell‐dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes
Journal of Biochemical and Molecular Toxicology · 2024-06 · 38 (6)
DOI: 10.1002/jbt.23719 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 19.05.2024. Verfasst von Abdullah Alqarni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostics Dental Sciences and Oral Biology, College of Dentistry, King Khalid University, Abha, Saudi Arabia. Hauptthemen laut MEDLINE: Exosomes, Neoplastic Stem Cells, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 134 Literaturangaben.
Abstract (Originalsprache)
Cancer stem cells (CSCs) are associated with the tumor microenvironment (TME). CSCs induce tumorigenesis, tumor recurrence and progression, and resistance to standard therapies. Indeed, CSCs pose an increasing challenge to current cancer therapy due to their stemness or self‐renewal properties. The molecular and cellular interactions between heterogeneous CSCs and surrounding TME components and tumor‐supporting immune cells show synergistic effects toward treatment failure. In the immunosuppressive TME, CSCs express various immunoregulatory proteins, growth factors, metabolites and cytokines, and also produce exosomes, a type of extracellular vesicles, to protect themselves from host immune surveillance. Among these, the identification and application of CSC‐derived exosomes could be considered for the development of therapeutic approaches to eliminate CSCs or cancer, in addition to targeting the modulators that remodel the composition of the TME, as reviewed in this study. Here, we introduce the role of CSCs and how their interaction with TME complicates immunotherapies, and then present the CSC‐based immunotherapy and the limitation of these therapies. We describe the biology and role of tumor/CSC‐derived exosomes that induce immune suppression in the TME, and finally, introduce their potentials for the development of CSC‐based targeted immunotherapy in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostics Dental Sciences and Oral Biology, College of Dentistry, King Khalid University, Abha, Saudi Arabia.
- Medical Laboratory Techniques Department, Al-Maarif University College, Anbar, Iraq.
- Department of Chemistry, University College of Duba, University of Tabuk, Tabuk, Saudi Arabia.
- School of Basic and Applied Sciences, Shobhit University, Gangoh, India.
- Department of Health and Allied Sciences, Arka Jain University, Jamshedpur, India.
- Department of Biotechnology and Genetics, Jain (Deemed-to-be) University, Bengaluru, India.
Zitieren
APA
Alqarni, A., Jasim, S. A., Altalbawy, F. M. A., Kaur, H., Kaur, I., Rodriguez-Benites, C., Deorari, M., Alwaily, E. R., Al-Ani, A. M., & Redhee, A. H. (2024). Challenges and opportunities for cancer stem cell‐targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell‐dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes. Journal of Biochemical and Molecular Toxicology, 38(6). https://doi.org/10.1002/jbt.23719
Vancouver
Alqarni A, Jasim SA, Altalbawy FMA, Kaur H, Kaur I, Rodriguez-Benites C, et al. Challenges and opportunities for cancer stem cell‐targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell‐dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes. Journal of Biochemical and Molecular Toxicology. 2024;38(6). doi:10.1002/jbt.23719
BibTeX
@article{Alqarni2024,
author = {Alqarni, Abdullah and Jasim, Saade Abdalkareem and Altalbawy, Farag M A and Kaur, Harpreet and Kaur, Irwanjot and Rodriguez-Benites, Carlos and Deorari, Mahamedha and Alwaily, Enas R and Al-Ani, Ahmed M and Redhee, Ahmed H},
title = {Challenges and opportunities for cancer stem cell‐targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell‐dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
volume = {38},
number = {6},
doi = {10.1002/jbt.23719}
}
EUVIMED